HALO logo
halo search icon
Innate Pharma SA Sponsored ADR
Innate Pharma SA Sponsored ADR
IPHA · NAS

Innate Pharma SA Sponsored ADR

US$2.20

Price Arrow0.17 (8.37%)
20/05/2026 04:00:00 PM
All-Consensus
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Innate Pharma SA Sponsored ADR Overview

IPHA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About IPHA

icon

Telephone

33.4.30.30.30.30

icon

Address

117, Avenue de Luminy, Marseille, Provence-Alpes-Cote-dAzur 13009

Description

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

IPHA Price Chart

Key Stats

Market Cap

US$197.14M

PE

12.90

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.17 - 2.63

Trade Value (12mth)

US$39,298.00

1 week

0.5%

1 month

34.44%

YTD

11.54%

1 year

-5.14%

All time high

11.95

Key Fundamentals

EPS 3 yr Growth

-19.20%

EBITDA Margin

NaN%

Operating Cashflow

-$59m

Free Cash Flow Return

-516.00%

ROIC

-484.60%

Interest Coverage

-127.20

Quick Ratio

1.30

Other Data

Shares Outstanding (Fully Diluted)

94m

HALO Sector

Healthcare

Next Company Report Date

25-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

IPHA Announcements

Latest Announcements

DateAnnouncements
19 May 26
13 May 26
12 May 26
06 May 26
23 April 26

IPHA Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-0.1-0.66-0.62locklocklock
EPS (Fully Diluted)
$locklocklocklock-0.1-0.66-0.62locklocklock
Growth
%locklocklocklock86.7-549.26.2locklocklock
PE
XlocklocklocklockN/AN/A12.9locklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Innate Pharma SA Sponsored ADR (IPHA:NAS)?
Halo FAQ
The current share price of Innate Pharma SA Sponsored ADR (IPHA:NAS) is USD$2.20.
What is the 52-week high share price for Innate Pharma SA Sponsored ADR (IPHA:NAS)?
Halo FAQ
The 52-week high share price for Innate Pharma SA Sponsored ADR (IPHA:NAS) is USD$2.63.
What is the 52-week low share price for Innate Pharma SA Sponsored ADR (IPHA:NAS)?
Halo FAQ
The 52-week low share price for Innate Pharma SA Sponsored ADR (IPHA:NAS) is USD$1.17.
What is the dividend yield for Innate Pharma SA Sponsored ADR (IPHA:NAS)?
Halo FAQ
Innate Pharma SA Sponsored ADR (IPHA:NAS) does not pay a dividend.
What was Innate Pharma SA Sponsored ADR (IPHA:NAS) last dividend payment?
Halo FAQ
Innate Pharma SA Sponsored ADR (IPHA:NAS) does not pay a dividend.
What is the franking level for Innate Pharma SA Sponsored ADR (IPHA:NAS)?
Halo FAQ
Innate Pharma SA Sponsored ADR (IPHA:NAS) has a franking level of 0.00%.
In which sector is Innate Pharma SA Sponsored ADR (IPHA:NAS) classified?
Halo FAQ
Innate Pharma SA Sponsored ADR (IPHA:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for Innate Pharma SA Sponsored ADR (IPHA:NAS)?
Halo FAQ
The current P/E ratio for Innate Pharma SA Sponsored ADR (IPHA:NAS) is 12.90.

See beyond the curve.

One solution for research, investing and portfolio management.